Compounds, compositions and methods for cancer treatment
AssigneesThe Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
InventorsTimothy A. Lewis, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Manuel Ellermann, Philip Lienau, Knut Eis, Antje Margret Wengner, Charlotte Christine Kopitz, Martin Lange
Life of this patent
Estimating the term…
Abstract
The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.
Claims16
A compound having the structure:
- or a pharmaceutically acceptable salt, or prodrug thereof.
A method of preparing compound 1, said method comprising the steps of
- reacting a compound of formula (IV)
- with pure morpholine at elevated temperatures, or with morpholine and a base, optionally in a polar aprotic solvent, at reflux temperature, to obtain Compound (V)
- which then is reacted with a strong base, in a polar aprotic solvent at low temperatures followed by addition of (C1-C4-alkyl)bromoacetate or (C1-C4-alkyl)chloroacetate neat or in a polar aprotic solvent,
- allowing the mixture to warm up from initial −78° C. to RT, optionally isolating the crude product, and then adding either hydrazine or hydrazine hydrate in a polar protic organic solvent under reflux temperature to obtain the racemic compound 1c
- and subsequently performing a separation of enantiomers of Compound 1c to obtain Compound 1 and Compound (1a)
- whereby optionally compound (1a) is converted into the racemic compound (1c) which could then be separated again in order to obtain Compound 1 and less of the initial amount of compound 1a isolated from the enantiomeric separation.
A method for the preparation of Compound 1 whereby compound (IV)
- is reacted with strong base in a polar aprotic solvent at low temperatures −78° to −60° C., followed by addition of (C1-C4-alkyl)bromoacetate or (C1-C4-alkyl)chloroacetate neat or in a polar aprotic solvent allowing the mixture to warm up from initial −78° C. to RT, optionally isolating the crude product, and then adding either hydrazine or hydrazine hydrate in a polar protic organic solvent under reflux temperature to produce compound (VII)
- and further allowing compound (VII) to react with pure morpholine at elevated temperatures, or with morpholine and a base in a polar aprotic solvent at reflux temperature to obtain Compound 1c
- and subsequently performing a separation of enantiomers of Compound 1c to obtain Compound 1 and Compound (1a)
- whereby optionally compound 1a is converted into racemic material which could then be separated in order to obtain Compound 1 and less of the initial amount of compound 1a.
Dependencies are inferred from the claim text.